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ABSTRACT
The aim of this article is to describe the current epidemiological situation of pertussis, as well as different short-term
strategies that have been implemented to alleviate this threat. The state of the art of the development of new vaccines that
are expected to provide long-lasting immunity against pertussis was also included.
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BRIEF OVERVIEW OF PERTUSSIS
EPIDEMIOLOGY
Pertussis or whooping cough is a respiratory disease mainly
caused by the bacteria Bordetella pertussis but also by B. para-
pertussis. The widespread use for over 50 years of pertussis
vaccines has markedly reduced the morbidity and mortality
associated with this disease. However, in the last few years the
incidence rates of pertussis have increased reaching about 16
million cases per year in the world, with approximately 200 000
deaths (WHO 2010b). Most of these cases were reported in de-
veloping countries, although several outbreaks were also de-
tected in industrialized countries, even those with high vacci-
nation rates (WHO 2010a; Clark 2014). In the Americas region,
the number of cases varies between 1500 and 48 000 (Partiarca
et al. 1988; Hozbor et al. 2009; Falleiros Arlant et al. 2014). In Ar-
gentina, the last outbreak occurred in 2011 when 76 deaths were
reported in infantswith less than 6months (Romanin et al. 2014).
In the USA, in 2012 was registered the highest outbreak since
1955, including 48 277 cases and 20 pertussis-related deaths. In-
cidence rates were very high in infants but also in 7- to 10-year-
old children and adolescents (13–14 years) http://www.cdc.gov/
pertussis/outbreaks/trends.html. Other industrialized country
from Europe that has experienced a notable outbreak is the
UK, in which in 2012 nearly 10 000 laboratory-confirmed
cases and 14 infant deaths have been reported (Public
Health England. Available at https://www.gov.uk/government/
publications/whooping-cough-pertussis-statistics, date last ac-
cessedNovember 2014). InAustralia, resurgence of pertussiswas
seen during 2008–12mainly in children less than 10 years of age,
in particular in 2–4 year old and 7–9 year old. Increase in hospi-
talizations in infants <1 year but without an increase in mortal-
ity in this age group was also detected in such country (Spokes,
Quinn and McAnulty 2010).
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The epidemiological situation detected in many countries
has driven health systems to analyze the possible causes of dis-
ease resurgence and revise their control actions to strengthen
disease control and/or implement short-term strategies to im-
prove the situation, at least for the most vulnerable population
represented by infants of less than 1 year of age. Several causes
that could explain the increase in the number of pertussis cases
have been proposed, most of them associated with the vaccines
currently in use: the decrease of vaccine effectiveness over time
(waning immunity) (Wendelboe et al. 2005), the selection pres-
sure exerted on bacterial circulating populations that has se-
lected pathogens able to escape immunity induced by the vac-
cine (Mooi, van Loo and King 2001) and/or the vaccine failure to
induce sterilizing immunity to the pathogen and consequently
to avoid transmission (Warfel, Zimmerman and Merkel 2014).
The first two proposed causes appear to have a greater impact in
those countries that use the primary series of vaccination acel-
lular pertussis vaccines (aP) instead of the classic whole-cell per-
tussis vaccines (wP) (Witt et al. 2013; Clark 2014; Lam et al. 2014;
Pawloski et al. 2014). Regarding waning immunity, a systematic
literature review and meta-analysis of the duration of protec-
tive immunity to pertussis after routine childhood immuniza-
tion with aP was recently performed (McGirr and Fisman 2015).
The authors estimated that the average duration of vaccine pro-
tection from aP is ∼3 years, assuming 85% vaccine efficacy. The
data reported also suggested that the odds of pertussis increase
by 1.33 times (95% confidence interval: 1.23–1.43) for every addi-
tional year since the last dose of aP.
Regarding pathogen adaptation, it has been reported that cir-
culating B. pertussis isolates differ from the strains used in vac-
cines production in their genotypes (Gzyl et al. 2001; Lee et al.
2003; Tsang et al. 2005; Bottero et al. 2007, 2012; King et al. 2008).
Within approximately two decades, strains with a novel allele
for the pertussis toxin (PT) promoter (ptxP3 strains) have nearly
completely replaced the previously dominant ptxP1strains in
many European countries, the USA and Australia (Advani et al.
2011; Lam et al. 2012; Petersen et al. 2012; Schmidtke et al. 2012;
Mooi, Van Der Maas and De Melker 2014) and also in Argentina.
The ptxP3 strains produce more Ptx in vitro and also pertactin
(Prn) and a number of other virulence genes, including a type
III secretion toxin and Vag8, a protein involved in complement
resistance.
The enhanced expression of the vaccine antigens Ptx and Prn
by ptxP3 strainswas confirmed at the protein level (de Gouw et al.
2014). van Gent et al. (2012) reported that the detected variation
in the promoter for PT and Prn contribute significantly to differ-
ences in colonization.
Additionally, in countries where acellular vaccineswere used
as the unique formulation against pertussis, an important in-
crease in the isolation of B. pertussis clinical isolates that do
not produce vaccine antigens has been reported, in particular in
those that do not express the adhesin pertactin (PRN(–)) (Hegerle
and Guiso 2014; Lam et al. 2014; Pawloski et al. 2014; Tsang et al.
2014). It was speculated that this loss probably provides a selec-
tive advantage for bacterial survival in vaccinated population.
In fact, evidence has been found showing that certain acellular
vaccines composed of three componentswere not as effective as
expected in controlling the infection caused by B. pertussis that
do not express PRN (Hegerle, Dore and Guiso 2014).
The third possibility was recently proposed by Warfel, Zim-
merman and Merkel (2014). These authors, using non-human
primates as a model for B. pertussis infection, found evidence on
the capacity of acellular vaccine to protect individuals against
disease but not against bacterial colonization. In their experi-
ments, infant baboons were vaccinated with three doses of aP
or wP vaccines and challenged with B. pertussis at 7 mo. Inter-
estingly, aP-vaccinated baboons can become asymptomatically
infected and readily transmitted B. pertussis to unvaccinated
contacts at the same rate than naı¨ve controls. In contrast,
wP vaccination induced a more rapid clearance compared
with naı¨ve and aP-vaccinated animals (Warfel, Zimmerman
and Merkel 2014). Key differences in T-cell immunity response
were observed since wP-vaccinated animals elicited strong B.
pertussis-specific T helper 17 (Th17) memory and Th1 memory,
whereas aP vaccination mainly induced a strong Th2 response
instead. The observations on the induced immune response cor-
relate well with that observed in humans (Fedele et al. 2010;
Higgs et al. 2012). In this sense, a recent study analyzed long-
term T-cell memory in adolescents primed with either wP or aP
and found that the Th1 response still remained stronger in ado-
lescents primedwithwP compared to aP (Smits et al. 2013). It was
hypothesized that Th1 cells promotes the production of protec-
tive opsonizing antibodies following pertussis vaccination and
infection by inducing IgG2a class switching in B cells (Ross et al.
2013). Two recent clinical studies corroborate the notion that aP
induces Th2 and Th1 responses in children and found no signif-
icant Th17 responses following vaccination (Schure et al. 2012,
2013)
The problems associated with the current vaccines used as
well as the strategies recommended and/or implemented to im-
prove the control of the disease in a short-term are discussed in
the following sections.
PROBLEMS ASSOCIATED WITH CURRENT
PERTUSSIS VACCINES AND WHO POSITION
wP was the first developed vaccine against the disease. With
the massive use of this vaccine in the 1950s, the incidence
and mortality associated with pertussis fell to very low levels
(Amirthalingam, Gupta and Campbell 2013). However, reports on
safety concerns in the 1970s shed doubt on the value of wP vac-
cines. These vaccines were associated not only with side effects
at the injection site but also with serious systemic reactions, in-
cluding whole limb swelling, febrile seizures and persistent cry-
ing (Cody et al. 1981; Jefferson, Rudin and DiPietrantonj 2003).
These adverse events and to lesser extent the low effectiveness
of selected wP vaccines contributed to reduce pertussis vaccine
acceptance in countries such as the United Kingdom, Italy, Ire-
land, Australia, West Germany and Russia (Jefferson, Rudin and
DiPietrantonj 2003; Klein 2014). Moreover, in the 1970s, Japan
and Sweden suspended their pertussis vaccination programs be-
cause of safety and effectiveness concerns, respectively (Sato,
Kimura and Fukumi 1984; Romanus, Jonsell and Bergquist 1987).
Thewidespread apprehension surroundingwP prompted the
development of acellular vaccines that contain purified proteic
antigenic components of B. pertussis. The first acellular vaccine
consisted in PT alone but then other surface attachment pro-
teins, i.e. filamentous hemagglutinin, pertactin (PRN) and two
fimbriae proteins (FIM 2 and FIM3) were added (Sato and Sato
1999; Klein 2014).
Though there is no evidence to suggest that wP vaccines
cause infant deaths, brain damage or severe neurological dis-
order neither contraindications to use them, the aP vaccines are
more accepted especially in industrialized countries. Indeed, in
these countries wP were gradually replaced by aP formulations
and currently most of the countries of Europe and USA only
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population confidence in pertussis containing vaccines and the
situation seemed to be under control for several years. How-
ever, as we mentioned before during the last two decades the
epidemiological situation of pertussis has changed. Several out-
breaks were reported supporting waning immunity and demon-
strating that children primed with wP vaccines had more last-
ing immunity than those primed with aP vaccines (Witt, Katz
andWitt 2012; Klein et al. 2013). A case-control clinical study de-
signed to assess the risk of pertussis among 10–17 year old dur-
ing the 2010 outbreak in California revealed that teenagers who
had received four aP doses were nearly six times more likely to
be PCR positive for pertussis than were those who had received
four doses of wP (OR 5.6, 95% CI 2.6–12.5) and had nearly four
times more chances to get infected likely than those who had
received a mix of vaccines (Klein et al. 2013). Another study also
found that the risk of pertussis was increased in school children
and adolescents whose infant vaccination schedule was com-
posed exclusively of aP doses compared with subjects who re-
ceived one wP dose (Witt, Katz and Witt 2012; Witt et al. 2013).
An investigation of the 2012 pertussis outbreak in Oregon
also showed that among children born during the transition
from wP to aP in 1997–99, those who underwent priming with
aP rather than wP vaccine had higher rates of reported pertus-
sis. The findings of this investigation concur with those from
Australia (Sheridan et al. 2012).
Under this context, in 2010 theWHO published a position pa-
per on the use of pertussis vaccines. This paper included among
others the following statements and recommendations: (1) the
efficacies of aP and wP vary depending upon the case definition
of pertussis used. However, the best aP vaccines have higher ef-
ficacy than low-efficacy wP vaccines but they may be less ef-
ficacious than the highest efficacy wP vaccines in preventing
whooping cough. (2) Protection against severe pertussis in in-
fancy and early childhood can be obtained after a primary series
of vaccination with wP or aP vaccine.
In November 2012, the Strategic Advisory Group of Experts
on immunization expressed concern regarding the resurgence of
pertussis in some industrialized countries despite high vaccine
coverage with aP vaccines. The switch from wP to aP vaccines
for primary infant immunization was proposed to be responsi-
ble at least in part for such resurgence, and therefore WHO rec-
ommended that such switch should only be considered if the
inclusion in the national immunization schedules of large num-
bers of doses (including several boosters) can be assured; this
has major financial implications due to the much higher cost of
aP vaccines and much larger number of doses required.
Countries currently using aP vaccines may continue using
this vaccine but should consider the need for additional booster
doses and strategies to prevent early childhoodmortality in case
of resurgence of pertussis.
STRATEGIES TO IMPROVE PERTUSSIS DISEASE
CONTROL
Previously to pertussis resurgence, the WHO recommended a
three-dose primary series, with the first dose administered at 6
weeks of age; subsequent doses should be given 4–8weeks apart,
at the age of 10–14 weeks and 14–18 weeks. The last dose of that
primary series should be completed by the age of 6 months. In
addition, a booster dose is recommended for children aged 1–
6 years, preferably during the second year of life. The booster
should be given≥6months after the last primary dose.With this
four-dose schedule (primary series plus booster), at least 6 years
of protection against pertussis is expected (WHO).
With the pertussis resurgence, the Advisory Committee on
Immunization Practices of the US Centers for Disease Control
and Prevention (CDC), Global Pertussis Initiative (GPI) and
other international and national entities have recommended
a booster for adolescents and adults in order to improve
disease control (Broder et al. 2006; CDC 2011a,b). Several
countries have recommended and/or implemented acellu-
lar booster doses with aP (Tdap) for adolescents (Argentina,
Australia, USA, France among others) and/or replaced the
decennial Td dose with a single or more doses of Tdap for
adults (including among others the USA, Australia, Austria,
Italia). Furthermore, some countries recommend selected
immunization of pregnant women, child care workers and
parents of newborns (e.g. Argentina, Austria and Germany)
(http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx).
The benefits of Tdap booster vaccination when applied to a
particular age group of adolescents or adults resulted to be ad-
equate only for the population group that receives the vaccine
during the first years after vaccination (Acosta et al. 2015; Haller
et al. 2015; Vandermeulen et al. 2015). However, immunization
of these groups does not impact over the incidence of disease
in more vulnerable population represented by the newborns
and infants with less than 6 months (Stein-Zamir et al. 2010;
Fabricius et al. 2013).
Recently, based on available evidence, the GPI recommended
maternal immunization during pregnancy as the primary strat-
egy to protect newborns and infants (Forsyth et al. 2015). If ma-
ternal immunization is not possible, or if families desire addi-
tional protective measures for their newborns, then it is recom-
mended that all individuals having close contact with infants 6
months old are immunized consistent with local health author-
ity guidelines. GPI state that a high priority should be given to
achieving a complete cocoon, defined as full immunization of
the family, since the robustness of protection against pertussis
is a function of the number of infant contacts vaccinated. If a
complete cocoon is not possible, then the next priority is vacci-
nation of both parents, followed by themother only. For families
using cocooning, immunization should occur during pregnancy
or immediately postpartum to prevent pertussis transmission to
infants 6 months old or less (Forsyth et al. 2015).
It is important to note, however, that data on clinical ef-
fectiveness of the different recently recommended vaccination
strategies against pertussis still remain limited. However, it is
increasingly clear that reducing the circulation of B. pertussis
and protecting infants against severe disease may be difficult to
achieve by a single approach, andmultiple immunization strate-
gies with current vaccines should be applied.
Due to the aforementioned situation, much interest is set in
developing new alternative options for antipertussis immuniza-
tion. The lack of an absolute correlate of protection has made
this task more difficult. Data from animal models and human
studies indicate that although antibodies may mediate protec-
tion, Th1 and Th17 cellular responses are responsible for long-
lasting protection (Mills et al. 2014). Since current acellular vac-
cines elicit mainly a Th2 response, several proposals have been
suggested to combine these vaccines with adjuvants that may
drive a Th1 response, at least for the priming doses (Allen and
Mills 2014). In this sense, the use of the TLR9 ligandCpGhas been
shown to accomplish this aim in themousemodel andmay rep-
resent an interesting alternative (Asokanathan, Corbel and Xing
2013). The addition of modified LPS molecules with an accept-
able safety profile to acellular antipertussis formulation has also
been proposed following this same rationale (Brummelman et al.
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outer membrane protein that has the capacity to trigger TLR2
response ant that may also be added to a multicomponent acel-
lular vaccine having a dual role of skewing Th response and also
having antigenic capacity per se (Dunne et al. 2015).
Since wP vaccines are being revalued over acellular vaccines
regarding their effectiveness (Witt et al. 2013), there are also
ongoing attempts to reduce its inherent toxicity by changing
the production process (Dias et al. 2013). Several researchers
have also identified vaccine candidates of potential interest to
be combined with the immunogens already in use in order to
broaden the protective capacity of acellular vaccines. Proteins
involved in iron sequestration may constitute alternative anti-
gens to be used following this strategy (Alvarez Hayes et al.
2011). The known virulence factor Adenilate cyclase-hemolysin
(AC-Hly) has been proposed to be considered for incorporation
in the vaccine (Sebo, Osicka and Masin 2014). Since the resid-
ual toxic activity may induce adverse responses, recombinant
toxin with changes in critical sites that affect its biological ac-
tivity without changing its protective capacity was generated
(Sebo, Osicka and Masin 2014). Similarly to PT toxin, the inher-
ent biological activity of AC induces adverse effects, which are
prevented by chemically detoxification of the protein by treat-
ments with cross-linking agents such as formaldehyde or glu-
taraldehyde. However, these treatments also affect protective
epitopes, resulting in a non-optimal protective capacity. There
are attempts to generate recombinant PT variants having low bi-
ological toxicity, without affecting its conformation and conse-
quently producing high quality of blocking antibodies (Seubert
et al. 2014). It has been proposed to use this newly formulated
antigen with different adjuvanting schemes in order to achieve
an adequate cellular response profile (Robbins et al. 2014). Fur-
thermore, other combinations of novel candidate immunogens
and adjuvants have been proposed (Polewicz et al. 2013), which
paves the way for future comparative studies or selection of the
appropriate antigen/adjuvant combination.
A complete different approach has been followed by Locht
and coworkers who generated an attenuated B. pertussis strain
by introducing several mutations in three key virulence fac-
tors showing the capacity of this strain to act as an attenuated
live vaccine when delivered intranasally (Mielcarek et al. 2006).
This vaccine has been shown to produce long-lasting protective
immunity associated with transient colonization in the mouse
model (Feunou et al. 2010) as well as generating B and Th1/Th17
immunity (Feunou, Bertout and Locht 2010). Additional muta-
tions in virulence factors such as adenilate cyclase that affects
the capacity of the vaccine strain BPZE1 to replicate in vivo were
shown to be detrimental to the protective capacity of this vac-
cine candidate (Lim et al. 2014). Since the preexisting antiper-
tussis immunity may affect the capacity of the vaccinal strain to
colonize and subsequently generate protective responses, BPZE1
has been postulated to be used shortly after birth, with the con-
sequent associated risks. It has been shown that using the BPZE1
as priming vaccination and subsequent doses of acellular vac-
cine recalls a Th1 response (Feunou et al. 2014), encouraging for
the use of this type of combinations. Based on results obtained
in preclinical models, this candidate was subjected to clinical
phase I trial on adult volunteers following a dose-escalation
scheme and showing minor safety events (Thorstensson et al.
2014). The generation of a B-cell response attributed to BPZE1
colonization was observed in participants of this randomized
trial (Jahnmatz et al. 2014). Studies are underway to move for-
ward the development of antipertussis vaccine following this
strategy.
OUTER MEMBRANE VESICLES AS AN
ATTRACTIVE CANDIDATE FOR PERTUSSIS
VACCINE
Gram-negative bacteria naturally release lipid bilayer vesicles
from the outermembrane that range in size from approximately
20 to 200 nm in diameter and enclose many native bacterial
antigens in the spherical particles. The vesicles function in di-
verse roles including facilitation of the infection progression
(Schroeder and Aebischer 2009; Schaar et al. 2011; Donato et al.
2012; Ercoli et al. 2015). Because of their immunogenic proper-
ties, self-adjuvanticity and ability to be taken up by mammalian
cells, outer membrane vesicles (OMVs) are attractive candidates
as vaccine delivery platforms. In fact, OMVs vaccines have al-
ready been administered to humans. The most successful use
of OMVs vaccines had been against serogroup B Neisseria menin-
gitidis (MenB) (Findlow et al. 2007). In Norway, Cuba and New
Zealand, licensed OMVs vaccines used in epidemics of MenB
had proven to be immunogenic and protective (Bjune et al. 1991;
Sierra et al. 1991). Research is ongoing to develop a global vesicle-
based vaccine to N. meningitidis because existing formulations
cover single meningococcal lineages with little cross-reactivity
(Granoff 2010; Zollinger et al. 2010). Recently, Zollinger et al.
showed in animal models that native OMVs design is poten-
tially safe and also broadly protective for possible use as a uni-
versal vaccine against meningococcal disease. This OMV-based
vaccine continues in development with clinical trials underway
(Zollinger et al. 2010).
The proven efficacy records of these OMVs vaccines together
with the knowledge that vesicles are produced by nearly all
species of Gram-negative bacteria (de Kleijn et al. 2000) pre-
sented the possibility of employing the OMV vaccination strat-
egy for prevention of other diseases. In this context, we have
demonstrated first that OMVs derived from B. pertussis can pro-
tect against intranasal pertussis challenge when administered
by either intraperitoneal or intranasal route in a mouse model
of infection (Roberts et al. 2008). Furthermore, we have shown
that our vaccine based on OMVs derived from B. pertussis is safe
and able to induce protection in mice against different B. per-
tussis genotypic backgrounds (Roberts et al. 2008; Asensio et al.
2011) including those not expressing the virulence factor per-
tactin (PRN) (manuscript in preparation). Furthermore, we ob-
served that this vaccine elicits a protective immune response
with a mixed Th1/Th2 profile with a robust antibody response
and also induce a long-term protection in a murine model (Gail-
lard et al. 2014).
We also developed a vaccine based on OMVs derived from B.
parapertussis that also showed to be safe and protective against
B. parapertussis infection and in less extent to B. pertussis (Bottero
et al. 2013).
Based on the excellent properties of both vaccines, we devel-
oped a vaccine, which combines OMVs derived from both Bor-
detella species. We have characterized the composition of the
pertussis OMVs finding at least 40 protein components, mostly
membrane-bound proteins (Roberts et al. 2008; Bottero et al.
2013). The presence of a large number of immunogens in the
vaccine formulation is important since this may avoid the ex-
cessive selective pressure conferred by a single or a few protec-
tive vaccine antigens as those present in aP vaccines. Our OMVs-
based vaccine candidate (OMVsBp+Bpp vaccine) exhibits indeed
adequate protection capacity against different B. pertussis ge-
netic background but also against B. parapertussis. In agreement
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induced Th1/Th2 and Th17 immune response. (manuscript
in preparation). All these properties open the possibility of
envisaging the use of Bordetella-OMVs-based vaccine mainly as
initial immunization strategy followed by boosters of classic aP
formulations.
Considering the aforementioned epidemiological situation
and the challenges to be solved by new developments, the data
presented here show that there are several alternatives under
development thatmay contribute in the future to enlarge the op-
tions for prophylactic vaccination against pertussis. In the short
term, plans for addressing the resurgence of pertussis should
include continued efforts to enhance immunization in children
on time. Strategies such as ‘cocooning’ and neonatal vaccina-
tion, immunization of pregnant mothers with aP seems to be
required to protect the most vulnerable members of the popu-
lation, infants who have not yet vaccinated. Longer term goals
include the development of new vaccines. For developed coun-
tries, new aP vaccines containingmore antigens/adjuvant in the
formulation appear to be a good strategy. However, for develop-
ing countries, which can not easily afford these vaccines due to
their expensive costs, new generation of wP with reduced toxi-
city seems to be potentially affordable approach. In the case of
OMVs-based vaccines, they resemble wP in the sense of provid-
ing a complex mix of antigens but with lower toxicity and low
cost. Thus, these vaccines appear to be feasible to be used both
in developed and developing countries.
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